Publication #6929

Reference
MSAN(2020)47
Name
H2-antagonists (cimetidine, famotidine and nizatidine)
Categories
Scottish Government Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS SCOTLAND DRUGS SAFETY RISKS PHARMACEUTICAL INDUSTRY DRUG THERAPY PHARMACEUTICAL SERVICES SUPPLIES
Description
1. Following supply issues affecting Ranitidine (MSAN (2019)22, and subsequent updates), suppliers of cimetidine, famotidine and nizatidine have reported an increase in demand, which has contributed to short term shortages.
 Famotidine 20mg tablets: Teva are out of stock with resupply date to be confirmed; Tillomed have limited stock with resupply date to be confirmed;
 Famotidine 40mg tablets: Teva expect to be back in stock w/c 1 June; Tillomed have limited stock with resupply date to be confirmed;
 Cimetidine 200mg tablets: Ennogen are back in stock; Medreich are out of stock with resupply date to be confirmed;
 Cimetidine 400mg tablets: Ennogen are out of stock until June 2021; Medreich are out of stock with resupply date to be confirmed;
 Cimetidine 800mg tablets: Ennogen are back in stock; Medreich are out of stock with resupply date to be confirmed;
 Nizatidine 150mg and 300mg tablets: Mylan are out of stock until the end of 2020; Medreich are out of stock with resupply date to be confirmed.

2. It is recommended that, where possible, patients are not switched to an alternative H2-receptor antagonist in the first instance as this may exacerbate a shortage of these products. There are currently sufficient supplies of oral omeprazole to manage an increase in demand.


Contact Name
Contact Email
Contact Address
Contact Phone

Created
2020-06-01 00:00:00


Click to go back to homepage